TGFB1 and cancer: Novel drugs that block TGF-β pathway have entered clinical evaluation, among which the most advanced is LY2157299, which has been confirmed in phase I studies to have antitumor activity in patients suffering from advanced LIHC through mainly affecting cancer cell migration and invasion [10].